What has the EU Joint Clinical Assessment (JCA) taught us about PICO planning?
Two years into the EU JCA, one lesson is clear: successful market access starts long before submission.
In this white paper, NAVLIN by EVERSANA experts share key learnings from supporting multiple JCA submissions and conducting AI-enabled PICO analyses across a range of therapeutic areas.
Discover how:
- Dual-stage PICO planning helps identify and address evidence gaps earlier in development.
- Continuous JCA monitoring is reshaping evidence planning.
- NAVLIN’s PICO Planner and JCA Insights Tracker help teams anticipate challenges before they impact access.
Read the white paper to explore practical strategies for strengthening submissions, identifying evidence gaps earlier, and building market access readiness in the evolving EU JCA landscape.
Author
Shivani Shah is Senior Consultant at EVERSANA and has around 6 years of experience working as consultant in pharmaceutical and life-science industry. Prior to joining EVERSANA, she has worked at one of the top…